Trial Profile
A multi-center randomized, open label, controlled study in primary liver transplantation comparing long term renal function in recipients treated with standard dose extended release tacrolimus alone and recipients treated with a combination of low dose extended release tacrolimus and low dose sirolimus
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Mar 2022
Price :
$35
*
At a glance
- Drugs Tacrolimus (Primary) ; Sirolimus
- Indications Liver transplant rejection
- Focus Therapeutic Use
- Acronyms LOL III
- 17 Mar 2022 Status changed from active, no longer recruiting to completed.
- 19 Aug 2021 Planned End Date changed from 1 Dec 2021 to 31 Dec 2021.
- 07 Nov 2019 Planned primary completion date changed from 1 Mar 2021 to 1 Jun 2021.